Corresponding Author: Jennifer A. Doudna, PhD, 2151 Berkeley Way, Berkeley, CA 94704 (doudna@berkeley.edu).
Conflict of Interest Disclosures: Dr Kan reported being a fellow in the Pediatric Scientist Development Program, supported by award K12-HD000850 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr Doudna reported being a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences; serving as a scientific advisory board member for Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences, and Inari; being a director at Johnson & Johnson; and having research projects sponsored by Biogen, Pfizer, AppleTree Partners, and Roche. In addition, Dr Doudna had a patent for CRISPR-Cas9 issued.
1.Jinek
M , Chylinski
K , Fonfara
I ,
et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
Science. 2012;337(6096):816-821.
PubMedGoogle ScholarCrossref 2.Stark
JM , Pierce
AJ , Oh
J ,
et al. Genetic steps of mammalian homologous repair with distinct mutagenic consequences.
Mol Cell Biol. 2004;24(21):9305-9316.
PubMedGoogle ScholarCrossref 6.Locatelli F, Frangoul H, Corbacioglu S, et al.
Efficacy and safety of a single dose of CTX001 for transfusion-dependent beta-thalassemia and severe sickle cell disease. June 12, 2022.
https://bit.ly/3Ak5Ao4